NCT01790126View on ClinicalTrials.gov

The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

March 4, 2013

Primary Completion Date

March 1, 2019

Study Completion Date

March 1, 2019

Conditions
Prostate Cancer
Interventions
DRUG

ARN-509

DRUG

LHRH Agonist

Trial Locations (5)

Unknown

Scottsdale

San Francisco

Chicago

Portland

Seattle

Sponsors
All Listed Sponsors
lead

Aragon Pharmaceuticals, Inc.

INDUSTRY

NCT01790126 - The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer | Biotech Hunter | Biotech Hunter